Cancer Care Ontario | Cancer Care Ontario

encorafenib - In combination with cetuximab or panitumumab in previously treated BRAF V600E-mutated metastatic colorectal cancer, according to clinical criteria

New Drug Funding Program

Panitumumab - In Combination with Encorafenib for Previously Treated Metastatic Colorectal Cancer

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

encorafenib,

PANitumumab

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Apr 2024

Regimen

DURV+TREM

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Funding:

New Drug Funding Program

Durvalumab in combination with Tremelimumab - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma (HCC)

New Drug Funding Program

Durvalumab in combination with Tremelimumab - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma (HCC)

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

tremelimumab,

durvalumab

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Aug 2024

Regimen

DARODOCE

Cancer Type:

Genitourinary,

Prostate

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Funding:

Exceptional Access Program

darolutamide - For the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

DOCEtaxel,

darolutamide

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Mar 2024

Drug

encorafenib

Other Name(s): Braftovi®

Quick Link(s):

Drug Monograph, Patient Info Sheet

Apr 2024

Drug

isatuximab

Other Name(s): Sarclisa®

Quick Link(s):

Drug Monograph, Patient Info Sheet

Mar 2024

Regimen

ENTR

Cancer Type:

Breast,

Endocrine,

Adrenal,

Neuroendocrine,

Pancreatic Neuroendocrine,

Parathyroid,

Thymoma,

Thyroid,

Gastrointestinal,

Anus,

Colorectal,

Esophagus,

Gastric / Stomach,

Gastrointestinal Stromal Tumours,

Hepatobiliary / Liver / Bile Duct,

Mesothelioma (Peritoneal),

Neuroendocrine (GI),

Pancreas,

Rectal,

Small bowel and appendix,

Genitourinary,

Bladder / Urothelial,

Penile,

Prostate,

Renal cell / Kidney,

Testis,

Gynecologic,

Cervix,

Endometrial,

Germ Cell,

Gestational Trophoblastic Disease,

Ovary,

Uterine Sarcoma,

Vagina,

Vulva,

Head and Neck,

Larynx,

Nasopharynx,

Oral,

Paranasal Sinus,

Pharynx,

Salivary Gland,

Squamous Cell,

Lung,

Neuroendocrine (Lung),

Non-Small Cell,

Small Cell,

Sarcoma,

Desmoid Tumour,

Ewing's,

Ewing's and Soft Tissue,

GIST,

Giant Cell Tumour,

Kaposi's Sarcoma,

Osteogenic / Bone,

Soft Tissue,

Uterine,

Wilm's Tumour,

Skin,

Basal Cell,

Melanoma,

Merkel Cell,

Squamous Cell,

Unknown Primary

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Funding:

Exceptional Access Program

entrectinib - Treatment of patients with unresectable locally advanced, or metastatic solid extracranial tumours documented to have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, according to specific criteria

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

entrectinib

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Sep 2024

Guidelines and Advice